Cyprotex Launches New "Mechanisms of Drug-Induced Toxicity" Guide
Get the latest biotech news where you want it. Sign up for the free
GenePool newsletter today!
11 July, 2013 - Cyprotex PLC, a specialist ADME-Tox Contract Research Organisation, today announces the launch of its third educational guide. Following the success of ‘Everything you needed to know about ADME but were too afraid to ask’ and ‘DDI regulatory guidance – an easy to follow guide’, Cyprotex introduces the latest addition entitled ‘Mechanisms of drug-induced toxicity’.
The new handbook provides a valuable resource for scientists in a range of disciplines who wish to gain an overview of the key mechanisms involved in drug-induced toxicity. It also includes details on the latest in vitro methodologies used for screening for drug-induced toxicity.
Research and knowledge in the field of in vitro toxicology is expanding rapidly. Cyprotex is at the forefront of this, developing novel cellular models and techniques for accurately predicting drug-induced toxicity, often working in conjunction with other groups. Cyprotex believes that the sharing of knowledge in this specialised field is important to further progress understanding and reduce late stage toxicology-related attrition.
Commenting on the launch of the new handbook, Dr. Anthony Baxter, Chief Executive Officer of Cyprotex, said: “There is a concerted effect within the pharmaceutical industry to reduce late stage attrition related to toxicity and move towards earlier in vitro screens which are more predictive of clinical outcome. Our ability to develop accurate in vitro models combined with in silico approaches has proved fruitful in this respect and Cyprotex are committed to continuing research in this important field. Our educational guides are well known and respected in the industry and I am delighted to launch our latest guide on Mechanisms of Drug-Induced Toxicity.”
To request a copy of our ‘Mechanisms of Drug-Induced Toxicity’ handbook, visit: http://www.cyprotex.com/toxguide/
For further information:
Cyprotex PLC
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
www.cyprotex.com
N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
Shaun Dobson
Jenny Wyllie
shaun.dobson@n1singer.com jenny.wyllie@n1singer.com www.n1singer.com
FTI Consulting
Tel: +44 (0) 20 7831 3113
Simon Conway
Mo Noonan
cyprotex@fticonsulting.com
www.fticonsulting.com
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services including CellCiphr® Premier and eCiphrCardio, and predictive modelling using PBPK and QSAR techniques including Cloe® PK for in vivo PK prediction.
For more information, see www.cyprotex.com.
Help employers find you! Check out all the jobs and post your resume.
11 July, 2013 - Cyprotex PLC, a specialist ADME-Tox Contract Research Organisation, today announces the launch of its third educational guide. Following the success of ‘Everything you needed to know about ADME but were too afraid to ask’ and ‘DDI regulatory guidance – an easy to follow guide’, Cyprotex introduces the latest addition entitled ‘Mechanisms of drug-induced toxicity’.
The new handbook provides a valuable resource for scientists in a range of disciplines who wish to gain an overview of the key mechanisms involved in drug-induced toxicity. It also includes details on the latest in vitro methodologies used for screening for drug-induced toxicity.
Research and knowledge in the field of in vitro toxicology is expanding rapidly. Cyprotex is at the forefront of this, developing novel cellular models and techniques for accurately predicting drug-induced toxicity, often working in conjunction with other groups. Cyprotex believes that the sharing of knowledge in this specialised field is important to further progress understanding and reduce late stage toxicology-related attrition.
Commenting on the launch of the new handbook, Dr. Anthony Baxter, Chief Executive Officer of Cyprotex, said: “There is a concerted effect within the pharmaceutical industry to reduce late stage attrition related to toxicity and move towards earlier in vitro screens which are more predictive of clinical outcome. Our ability to develop accurate in vitro models combined with in silico approaches has proved fruitful in this respect and Cyprotex are committed to continuing research in this important field. Our educational guides are well known and respected in the industry and I am delighted to launch our latest guide on Mechanisms of Drug-Induced Toxicity.”
To request a copy of our ‘Mechanisms of Drug-Induced Toxicity’ handbook, visit: http://www.cyprotex.com/toxguide/
For further information:
Cyprotex PLC
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
www.cyprotex.com
N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
Shaun Dobson
Jenny Wyllie
shaun.dobson@n1singer.com jenny.wyllie@n1singer.com www.n1singer.com
FTI Consulting
Tel: +44 (0) 20 7831 3113
Simon Conway
Mo Noonan
cyprotex@fticonsulting.com
www.fticonsulting.com
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services including CellCiphr® Premier and eCiphrCardio, and predictive modelling using PBPK and QSAR techniques including Cloe® PK for in vivo PK prediction.
For more information, see www.cyprotex.com.
Help employers find you! Check out all the jobs and post your resume.